South Korea’s BiocurePharm To Produce Biosimilars In Thailand
This article was originally published in PharmAsia News
Executive Summary
SEOUL - South Korean biopharmaceutical company BiocurePharm signed a memorandum of understanding with Thailand pharmaceutical distributor Kwang Tiang Dispensary to build a $20 million plant in Thailand to produce five types of biosimilar products for anemia and hepatitis, BiocurePharma announced Nov. 13
You may also be interested in...
Venture Capitalist Sheds Light On Market, Funding Options – Bio Korea (Part 1 of 2)
OSONG, South Korea - Venture capitalists are seeing the biggest returns from technology platforms or single-project financing, Hui-Hsing Ma, venture partner with TVM Capital told Bio Korea attendees.
Asia Partnerships Critical To Big Pharma’s Drying Pipelines, Merck Exec Tells Bio Korea (Part 2 of 2)
[Editor's note: This is part two of a two-part story from Bio Korea; part one was published in PharmAsia News, Oct. 12, 2008.]
Fresh Concerns Over Biosimilar ESA Use In Thailand Raises Takeda’s Hematide Prospects
SHANGHAI - Fresh safety concerns could be raised over the use of biosimilar erythropoietin stimulating agents after a patient in Thailand, who received an epoetin alfa biosimilar, developed ESA-related pure red cell aplasia, according to Baird analyst Christopher Raymond